AzTrials
AzTrials

Prostate CancerPRO-TRACTNCT07847385

Tractography-Guided Nerve-Sparing in Prostate Cancer

A study testing Prostate Tractography for Nerve-Sparing in people with Prostate Cancer and Erectile Dysfunction Following Radical Prostatectomy, run by Massimo Valerio at 1 site in Switzerland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Radical prostatectomy (RP) is an effective treatment leading to a high rate of oncological control. However, despite advances in robot-assisted RP, the genito-urinary function, especially erectile function and urinary continence, may be significantly impaired after surgery. Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
Prostate Tractography for Nerve-Sparing
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
1 siteSwitzerland
Study dates
1 Sep 2026to 1 Apr 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histological confirmed diagnosis of prostate cancer (PCa) based on prostate biopsy
  • Multidisciplinary indication for radical prostatectomy, validated by the Urology Tumor Board
  • No prior treatment of prostate cancer
  • Capacity to provide informed consent

Who cannot join

  • Unwillingness to participate.
  • Pre-existing impaired sexual function before surgery (IIEF5 Score of ≤21)
  • Diagnosis of neuropathy
  • Inability to comply with study procedure (e.g. due to language barriers, psychological disorders, dementia, anxiety/claustrophobia during pelvic MRI etc.) or medical contraindications to MRI

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Vincent Benard, Resident contact

+ 41 79 553 62 68

vincent.benard@hug.ch

Laurence Zulianello, PhD contact

+ 41 22 372 79 70

laurence.zulianello@hug.ch

Switzerland1 site, 1 recruiting
  • Hôpitaux Universitaires de Genève - Dept de Chirurgie - Service d'Urologie

    Geneva, Canton of Geneva, 1205

    Vincent Benard, Resident, + 41 79 553 62 68, vincent.benard@hug.ch

    Olivier Windisch, MD, + 41 79 553 31 98, olivier.windisch@hug.ch

    Recruiting

Other trials in Switzerland

About this study

Official title: PRO-TRACT: Prostate Tractography for Optimized Nerve-Sparing - A Pilot Study

Radical prostatectomy (RP) is an effective treatment leading to a high rate of oncological control. However, despite advances in robot-assisted RP, the genito-urinary function, especially erectile function and urinary continence, may be significantly impaired after surgery.

Our study aims to characterize and map the nerve fibers surrounding the prostate before and after surgery using diffusion tensor magnetic resonance imaging (DTI), a non-invasive magnetic resonance imaging (MRI) technique. This relatively new technology, combined with the 3D tractography software, will allow us to create a personalized 3D model of the periprostatic nerves. This virtual model will help us to assess the nerve bundles and how the surgery impacts their integrity. DTI and 3D reconstruction will be performed before and 6 months after surgery.

Read more

The pre-surgery 3D virtual model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organization. At the post-surgery level, the 3D virtual model of the nerve bundles will be compared to the pre-surgery model. Post-treatment changes at 6 months may help assess nerve preservation and their relationship with erectile (dys)function.

The main questions the clinical study aims to answer are:

  1. Post-treatment DTI-Tractography parameter changes at 6 months may help assess nerve recovery and their relationship with erectile (dys)function (PROMs - IIEF-5 score)
  2. Post-treatment DTI-Tractography parameter changes at 6 months may help assess their relationship with urinary function
  3. At the post-surgery level, the 3D virtual model of the nerve bundles will be compared to the pre-surgery 3D model.
  4. The pre-surgery 3D virtual model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organization (mean surgery time, surgeon feedback assessment, etc., will be evaluated.) Tumor location based on the 3D model will also be explored.
Read the detailed description

In Switzerland and Western countries, prostate cancer (PCa) is the most frequently diagnosed solid cancer in men and represents the second leading cause of cancer-related deaths. Similarly, in Geneva, between 1995 and 2021, PCa has been the most common cancer with 8,373 new cases reported.

For patients with prolonged life expectancy harboring high-risk and intermediate-risk disease, radical prostatectomy (RP) is one of the gold standard treatments. While RP is a safe and effective surgical procedure leading to a high rate of cancer control, the genito-urinary function can be severely impaired after surgery since the prostate is closely surrounded by neurovascular fibers that are critical for urinary continence and erectile function. In 1982, Walsh developed the nerve-sparing (NS) procedure to preserve the neurovascular bundles (NVBs) . Nevertheless, accurately identifying the NVBs still remains a challenge nowadays. Despite the advancements made in the area of precision surgery with the advent of 3D robotic-assisted RP (RARP) as well as preoperative planning (particularly with Multiparametric magnetic resonance imaging (mpMRI) providing information about tumor localization and extracapsular extension), erectile dysfunction (ED) is currently the most common post-operative sequela occurring in up to 74.7% of patients. One of the key reasons is linked to the fact that the NVBs are not clearly visible during surgery and are in contact with the prostatic capsule.

Novel intraoperative imaging modalities have emerged to solve this unmet clinical need. First, it has been suggested that assistance can be provided by intraoperative transrectal ultrasound (TRUS) eventually combined with a robotic manipulator. TRUS can identify key anatomical landmarks. However, it is rarely used due to the poor spatial resolution. Second, electrical nerve stimulation offers fast functional feedback for nerve mapping. Although this solution is deliverable, its inconsistent clinical response reduces its efficacy and usefulness. Third, fluorescent imaging allows for a real-time assessment, but its clinical use is limited due to, among others,the toxicity of dyes.

Tractography, mainly used in brain surgery, is an advanced non-invasive imaging technique relying on diffusion tensor imaging (DTI) and algorithms to reconstruct three-dimensional nerve fiber pathways by analyzing directional movement of water molecules in tissues The accuracy of DTI Tractography heavily relies on sophisticated protocols and highly developed technical parameters, which also includes the post-processing aspects. For instance, the number of gradient diffusion directions, b-values affecting the signal-to-noise ratio (SNR) and tract fiber length play a key role, as studied in Nordbrøden's thesis focusing on providing an optimized protocol for periprostatic fiber nerve tracking. Due to inherent complexity, despite being a promising tool, application of tractography for NVB mapping preoperatively has not been well studied yet. To improve functional outcomes, surgeons should be able to rely on a patient-tailored anatomical map to provide personalized nerve-sparing surgery.

Moreover, three-dimensional virtual model (3DVM), reconstructed from classical preoperative MRI done during the diagnostic pathway, are gaining popularity in RARP. Various formats are described; for instance, Virtual Reality (VR) uses a fullly digital immersive environment, whereas Augmented Reality (AR) overlays the 3D model onto the intraoperative view. However, integration of such a tool into clinical practice faces many challenges at each step of the procedure. First, when generating the model, suboptimal image quality and the difficult segmentation task needed for surface rendering (SR) could generate anatomical inaccuracy. Secondly, in AR, the 3DVM needs to be registered to the patient's anatomy (landmarks) using manual or semi-automatic techniques, with fully-automatic registration being the subject of ongoing research . Nonetheless, Schiavina et al (2021) using a manual registration accurately managed a real-time identification of the index lesion with the downside of having a dedicated 3DVM manipulator changing the NS plan in 38.5%.

In this context, given the absence of histopathological validation possible for Tractography, the rationale of this pilot study is to leverage the benefits of DTI imaging for nerve identification and to translate them directly during the surgery.

The trial relies on two distinct parts.

  • First, pre- and postoperative imaging will allow assessment of the neurovascular structures before and after the procedure, to evaluate the volumetry and integrity of the neurovascular bundles and how surgery impacted this. These results will be correlated with patients' functional outcome.
  • Second, the images acquired with the preoperative imaging will be reconstructed in a 3D Tractography Virtual Model (3DTVM) that will be used for intraoperative AR fusion. In this context, the surgeon could have a visual guide on the imaging data directly in the operative room (OR). No change in the surgical technique will occur by the use of this technique within this pilot study.

As this pilot study relies mostly on DTI MRI, a non-invasive modality that does not use a contrast agent, and excludes fluorescent dye administration or electrical stimulation, participant burden is limited to the need for this acquisition. As to the first part, according to the Ordinance on Human Research with the Exception of Clinical Trials dated 20 September 2013 and entered into force on 1st January 2014, and particularly Article 7, MRI scans without a contrast medium is associated with minimal risks and burdens and hence falls into the scope of Category A. As to the second part, the AR guidance is purely a non-invasive software-based overlay of MRI data onto the surgeon's view where no additional biological material collection is needed. There will be no new incisions or instruments beyond standard procedure (same surgical steps, trocar placement, dissection planes, etc.). Therefore, this second part is also associated to minimal risks and burdens and falls as well into the scope of Category A.

To address all these challenges, our institution is particularly adequate for many reasons. First, RARP is a procedure performed at an expert-level according to the European Cancer Center Certification Program. Second, prior to each surgery, the case is discussed in a multi-disciplinary setting with proofreading of the MRI by an expert uro-radiologist, Dr. Thomas De Perrot (according to European Society of Urogenital Radiology (ESUR) and EAU Section of Urologic Imaging (ESUI); more than 1000 interpreted MRI). The NS approach can therefore be safely chosen prior to surgery based on radiologic-clinical parameters. Pr. Felix Kurz is a renowned specialist in peripheral nerve imaging while Pr. Michele Diana is a pioneer in AR surgery and multi-level imaging surgical guidance . In addition, the Diagnostic Department, together with the CIBM Center for Biomedical Imaging, received the state-of-the-art MAGNETOM Cima.X (Siemens Healthineers AG, Erlangen, Germany) in June 2025. This advanced 3.0-T MRI system offers the highest magnetic gradients available in routine clinical imaging-reaching up to 200 mT/m. These exceptional gradients are specifically engineered for high-performance diffusion MRI measurements, reducing acquisition times and improving image quality through higher signal-to-noise ratio. In addition to all of the above, the HUG surgical department has performed Robotic AR surgery since 2011.

Regarding the "sex and gender" dimensions, the study concerns patients with PCa.

Being tested
Prostate Tractography for Nerve-Sparing
Keywords
Prostate cancer, Robot-assisted Prostatectomy, Erectile dysfunction, Nerve-sparing, Diffusion tensor imaging, Tractography, Augmented reality, 3D virtual model of nerve fibers for surgical guidance, Low-risk prostate cancer, Intermediate-risk prostate cancer
Medical subject headings
Prostatic Neoplasms, Erectile Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Prostate Tractography for Nerve-SparingProcedure or surgery

    Tractography will be performed according to established best practices. To create the 3DVM, a high-performance workstation equipped with a high-end GPU will be used. ROI placement for nerve tractography and segmentation tasks will be performed semi-automatically using a previously trained nnU-Net pipeline. All inference will be strictly performed locally on this dedicated machine resulting in 4 segment masks (Prostate, Urethra, Index Lesion, Seminal Vesicles) that will be manually reviewed and corrected. The subsequent reconstructed Tractography bundles will be added to create the 3DTVM.

    The 3DTV model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organizations (mean surgery time, surgeon feedback etc will be evaluated.)

Study groups in NCT07847385
Study groupRoleWhat they receive
Participants with prostate cancer undergoing robot-assisted radical prostatectomy.Experimental3 visits are related to the research protocol 1. Informed consent (Day - 30) 2. Preoperative MRI (DTI acquisition) and preoperative PROMs (day -14) 3. Postoperative MRI (DTI acquisition) and postoperative PROMs (day +180) The tractography will be performed according to established best practices. Robot-assisted PR (Day 0) is performed according to standard practice and is not part of the research-specific procedure.
Receives: Procedure: Prostate Tractography for Nerve-Sparing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of erectile function at 6-month.

    Imaging versus Patient-Reported Outcome Measure (PROM).

    Measured: From surgery (day 0) and at the 6-month follow-up (day 180).

Secondary outcomes (3)
  1. 1. Evaluation of urinary function at 6 month follow-up.

    Imaging versus Urinary Function Patient-Reported Outcome Measure (PROM).

    Measured: From surgery (day 0) and at the 6-month follow-up (day 180).

  2. Assessment of the feasibility of augmented reality using tractography-based 3D model.

    To document the feasibility of augmented reality using a tractography model (operative time).

    Measured: At surgery (day 0)

  3. 3. Concordance of pre- and postoperative Diffusion Tensor Imaging.

    Evolution of nerve integrity after surgery

    Measured: At the end of the 6-month follow-up (day 180)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Sep 2026
  2. Study start1 Sep 2026
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion1 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Prospective exploratory pilot study
Masking
None (open label)
Enrolment
23 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07847385
Sponsor's protocol ID
2025-01992
Other IDs
2025
Acronym
PRO-TRACT
Status last verified
Sep 2026
First submitted
31 Aug 2026
Last updated
29 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Exploratory study with a small number of participants

Questions about this trial

What is this clinical trial studying?

A study testing Prostate Tractography for Nerve-Sparing in people with Prostate Cancer and Erectile Dysfunction Following Radical Prostatectomy, run by Massimo Valerio at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Vincent Benard, Resident (+ 41 79 553 62 68, vincent.benard@hug.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of erectile function at 6-month. (time frame: From surgery (day 0) and at the 6-month follow-up (day 180).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in